Pemigatinib in the real-world management of advanced intrahepatic FGFR2-positive cholangiocarcinoma
Introduction. Cholangiocarcinoma (CC) is one of the most aggressive malignant tumors of the hepatobiliary tract with a poor prognosis, especially at the late stages. The targeted therapy with pemigatinib, a selective FGFR2 inhibitor, can be administered in a proportion (10–15%) of patients with intrahepatic cholangi...